Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

[Background] Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.

Detalhes bibliográficos
Autores: Rodríguez-Lescure, Álvaro, Gallego, Javier, García-Alfonso, Pilar, Massuti Sureda, Bartomeu, Márquez, Raúl, Calvo, Lourdes, Sánchez Rovira, Pedro, Antón, Antonio, Chacón, José Ignacio, Ciruelos, Eva, Ponce, Jose Juan, Santaballa, Ana, Valladares-Ayerbes, Manuel, Dueñas, María Rosario, Alonso, Vicente, Aparicio, Jorge, Encinas, Sara, Robles, Luis, Escudero, María José, Caballero, Rosalía, Bezares, Susana, Haba-Rodriguez, Juan de la
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/386340
Acesso em linha:http://hdl.handle.net/10261/386340
https://api.elsevier.com/content/abstract/scopus_id/85189294400
Access Level:acceso abierto
Palavra-chave:Metastatic colorectal cancer
Bevacizumab
Blood pressure
Metastatic breast cancer
id ES_f96a8f8cf929fc778215f4e322f93c7e
oai_identifier_str oai:digital.csic.es:10261/386340
network_acronym_str ES
network_name_str España
repository_id_str
spelling Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) studyRodríguez-Lescure, ÁlvaroGallego, JavierGarcía-Alfonso, PilarMassuti Sureda, BartomeuMárquez, RaúlCalvo, LourdesSánchez Rovira, PedroAntón, AntonioChacón, José IgnacioCiruelos, EvaPonce, Jose JuanSantaballa, AnaValladares-Ayerbes, ManuelDueñas, María RosarioAlonso, VicenteAparicio, JorgeEncinas, SaraRobles, LuisEscudero, María JoséCaballero, RosalíaBezares, SusanaHaba-Rodriguez, Juan de laMetastatic colorectal cancerBevacizumabBlood pressureMetastatic breast cancer[Background] Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.[Methods] This prospective observational study conducted by GEICAM Spanish Breast Cancer Research Group included metastatic breast (MBC) or colorectal (mCRC) cancer patients treated with bevacizumab-containing chemotherapy as first-line treatment. Blood pressure (BP) levels were measured (conventional and 24-h Holter monitoring) at baseline and up to cycle 3. Primary endpoint assessed BP levels increase as predictive factor for progression-free survival (PFS). Germline DNA methylation profile was explored in pre-treatment blood samples; principal component analysis was used to define an epigenetic predictive score for increased BP levels.[Results] From Oct-2012 to Jul-2016, 143 (78 MBC and 65 mCRC) patients were included. The incidence of AHT according to guidelines was neither predictive of PFS nor of best overall tumor response (BOR). No statistically significant association was observed with systolic BP nor diastolic BP increment for PFS or BOR. Grade 3 and 4 adverse events were observed in 37 and 5% of patients, respectively. We identified 27 sites which baseline methylation status was significantly associated to BP levels increase secondary to bevacizumab-containing chemotherapy.[Conclusions] Neither the frequency of AHT nor the increase of BP levels were predictive of efficacy in MBC and mCRC patients treated with bevacizumab-containing chemotherapy.[Clinical trial registry] ClinicalTrials.gov Identifier: NCT01733628.The study was sponsored by GEICAM Spanish Breast Cancer Group and has received funding from Roche Farma S.A. for some independent medical education activities and research projects performed by the Group in which all authors collaborated. It also has received a grant from Instituto de Salud Carlos III (PI15/00516). And from Sociedad Española de Oncología Médica (SEOM FECMA 2018).Peer reviewedSpringerRocheInstituto de Salud Carlos IIISociedad Española de Oncología MédicaRodríguez-Lescure, Álvaro [0000-0002-6823-5290]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/386340https://api.elsevier.com/content/abstract/scopus_id/85189294400reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.1007/s12094-024-03411-whttps://doi.org/10.1007/s12094-024-03411-wSíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3863402026-05-22T06:33:51Z
dc.title.none.fl_str_mv Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
title Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
spellingShingle Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
Rodríguez-Lescure, Álvaro
Metastatic colorectal cancer
Bevacizumab
Blood pressure
Metastatic breast cancer
title_short Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
title_full Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
title_fullStr Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
title_full_unstemmed Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
title_sort Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
dc.creator.none.fl_str_mv Rodríguez-Lescure, Álvaro
Gallego, Javier
García-Alfonso, Pilar
Massuti Sureda, Bartomeu
Márquez, Raúl
Calvo, Lourdes
Sánchez Rovira, Pedro
Antón, Antonio
Chacón, José Ignacio
Ciruelos, Eva
Ponce, Jose Juan
Santaballa, Ana
Valladares-Ayerbes, Manuel
Dueñas, María Rosario
Alonso, Vicente
Aparicio, Jorge
Encinas, Sara
Robles, Luis
Escudero, María José
Caballero, Rosalía
Bezares, Susana
Haba-Rodriguez, Juan de la
author Rodríguez-Lescure, Álvaro
author_facet Rodríguez-Lescure, Álvaro
Gallego, Javier
García-Alfonso, Pilar
Massuti Sureda, Bartomeu
Márquez, Raúl
Calvo, Lourdes
Sánchez Rovira, Pedro
Antón, Antonio
Chacón, José Ignacio
Ciruelos, Eva
Ponce, Jose Juan
Santaballa, Ana
Valladares-Ayerbes, Manuel
Dueñas, María Rosario
Alonso, Vicente
Aparicio, Jorge
Encinas, Sara
Robles, Luis
Escudero, María José
Caballero, Rosalía
Bezares, Susana
Haba-Rodriguez, Juan de la
author_role author
author2 Gallego, Javier
García-Alfonso, Pilar
Massuti Sureda, Bartomeu
Márquez, Raúl
Calvo, Lourdes
Sánchez Rovira, Pedro
Antón, Antonio
Chacón, José Ignacio
Ciruelos, Eva
Ponce, Jose Juan
Santaballa, Ana
Valladares-Ayerbes, Manuel
Dueñas, María Rosario
Alonso, Vicente
Aparicio, Jorge
Encinas, Sara
Robles, Luis
Escudero, María José
Caballero, Rosalía
Bezares, Susana
Haba-Rodriguez, Juan de la
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Roche
Instituto de Salud Carlos III
Sociedad Española de Oncología Médica
Rodríguez-Lescure, Álvaro [0000-0002-6823-5290]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Metastatic colorectal cancer
Bevacizumab
Blood pressure
Metastatic breast cancer
topic Metastatic colorectal cancer
Bevacizumab
Blood pressure
Metastatic breast cancer
description [Background] Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/386340
https://api.elsevier.com/content/abstract/scopus_id/85189294400
url http://hdl.handle.net/10261/386340
https://api.elsevier.com/content/abstract/scopus_id/85189294400
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.1007/s12094-024-03411-w
https://doi.org/10.1007/s12094-024-03411-w
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425092930306048
score 15,811543

Registos relacionados